Sign up online today & collaborate
or click here to find out more
Bristol-Myers Squibb’s Opdivo has launched for lung cancer in the UK, becoming the first immunotherapy available for the disease in the country.
The launch follows EU approval for the indication earlier this month.
Opdivo (nivolumab) belongs to a class of drugs known as PD-1 inhibitors, which are currently leading the charge in the promising area of immuno-oncology.
For more click here